Receptors, Antigen, T-Cell
"Receptors, Antigen, T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
| Descriptor ID |
D011948
|
| MeSH Number(s) |
D12.776.543.750.705.816.824
|
| Concept/Terms |
Receptors, Antigen, T-Cell- Receptors, Antigen, T-Cell
- T-Cell Antigen Receptor
- Antigen Receptor, T-Cell
- Receptor, T-Cell Antigen
- T Cell Antigen Receptor
- T-Cell Receptors
- Receptors, T-Cell
- T Cell Receptors
- T-Cell Receptor
- Receptor, T-Cell
- T Cell Receptor
- Receptors, T-Cell Antigen
- Receptors, T Cell Antigen
- T-Cell Antigen Receptors
- Antigen Receptors, T-Cell
- Antigen Receptors, T Cell
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Antigen, T-Cell".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Antigen, T-Cell".
- Receptors, Antigen, T-Cell
- Complementarity Determining Regions
- Receptor-CD3 Complex, Antigen, T-Cell
- Receptors, Antigen, T-Cell, alpha-beta
- Receptors, Antigen, T-Cell, gamma-delta
This graph shows the total number of publications written about "Receptors, Antigen, T-Cell" by people in this website by year, and whether "Receptors, Antigen, T-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 2 | 1 | 3 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 4 | 5 |
| 2002 | 2 | 6 | 8 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 3 | 4 |
| 2006 | 3 | 0 | 3 |
| 2007 | 1 | 3 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 2 | 4 |
| 2010 | 3 | 3 | 6 |
| 2011 | 4 | 1 | 5 |
| 2012 | 2 | 1 | 3 |
| 2013 | 4 | 4 | 8 |
| 2014 | 5 | 4 | 9 |
| 2015 | 5 | 6 | 11 |
| 2016 | 6 | 1 | 7 |
| 2017 | 17 | 8 | 25 |
| 2018 | 11 | 3 | 14 |
| 2019 | 8 | 6 | 14 |
| 2020 | 11 | 9 | 20 |
| 2021 | 7 | 5 | 12 |
| 2022 | 1 | 15 | 16 |
| 2023 | 0 | 15 | 15 |
| 2024 | 4 | 6 | 10 |
| 2025 | 4 | 4 | 8 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Antigen, T-Cell" by people in Profiles.
-
Single-cell TCR mapping reveals spatially coordinated T cell states in head and neck cancer. Sci Immunol. 2026 Apr 10; 11(118):eaec3133.
-
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. Nat Biomed Eng. 2026 Apr; 10(4):803-814.
-
Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor. Nat Commun. 2026 Feb 04; 17(1):1349.
-
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR. Blood Adv. 2025 Nov 11; 9(21):5460-5472.
-
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis. Blood Adv. 2025 Nov 11; 9(21):5489-5500.
-
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025 Oct 28; 9(20):5249-5262.
-
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Adv. 2025 Oct 14; 9(19):5070-5084.
-
Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. Transplant Cell Ther. 2025 Dec; 31(12):1000.e1-1000.e11.
-
IL-7 armed binary CAR T cell strategy to augment potency against solid tumors. Front Immunol. 2025; 16:1618404.
-
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025 Apr; 31(4):1125-1129.